Drug Evaluation

Department of Medical Oncology, BC Cancer Vancouver Centre, Vancouver, BC, V5Z 4E6, Canada

Department of Urological Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, V6H 3Z6, Canada

Search for more papers by this author

Christian Kollmannsberger

*Author for correspondence: Tel.: +1 604 877 6000;

E-mail Address: ckollmannsberger@bccancer.bc.ca

https://orcid.org/0000-0002-6329-761X

Department of Medical Oncology, BC Cancer Vancouver Centre, Vancouver, BC, V5Z 4E6, Canada

Search for more papers by this author

Published Online:28 Aug 2020https://doi.org/10.2217/fon-2020-0586

View article

Abstract

Owing to an improved understanding of the immunobiological profile of renal cell carcinoma (RCC), the past few years have ushered in significant changes in systemic therapies for advanced stage RCC. First-line treatment with single-agent tyrosine kinase inhibitors (TKI) has been virtually replaced for most patients by immunotherapy combinations. The first of such treatments was the dual immune checkpoint inhibitor combination of ipilimumab and nivolumab. More recently, the combination of an immune checkpoint inhibitor and a TKI has also moved into the first-line setting. This review summarizes the pharmacologic properties, evidence for use and safety of avelumab, a PD-L1 inhibitor and axitinib a small-molecule TKI, each as monotherapy, and in combination for the management of metastatic RCC.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Atkins MB, Choueiri TK. Epidemiology, pathology, and pathogenesis of renal cell carcinoma. (2020). https://www.uptodate.com/contents/epidemiology-pathology-and-pathogenesis-of-renal-cell-carcinoma?search=renal cell carcinoma&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3
Google Scholar
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
MedlineGoogle Scholar
3. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs – part B: prostate and bladder tumours. Eur. Urol. 70(1), 106–119 (2016).
MedlineGoogle Scholar
4. Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 369(8), 722–731 (2013).
Medline CASGoogle Scholar
5. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373(19), 1803–1813 (2015).
Medline CASGoogle Scholar
6. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192(12), 5451–5458 (2014).
Medline CASGoogle Scholar
7. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(22), 3584–3590 (2009).
Medline CASGoogle Scholar
8. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13(3), 688–696 (1995).
Medline CASGoogle Scholar
9. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316(15), 889–897 (1987).
Medline CASGoogle Scholar
10. Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ. Regulation of HIF by the von Hippel–Lindau tumour suppressor: implications for cellular oxygen sensing. IUBMB Life 52(1), 43–47 (2001).
Medline CASGoogle Scholar
11. Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr. Oncol. Rep. 11(2), 94–101 (2009).
Medline CASGoogle Scholar
12. Sánchez-Gastaldo A, Kempf E, González del Alba A, Duran I. Systemic treatment of renal cell cancer: a comprehensive review. Cancer Treat. Rev. 60, 77–89 (2017).
Medline CASGoogle Scholar
13. Rini B, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised Phase III trial. The Lancet 378(9807), 1931–1939 (2011).
Medline CASGoogle Scholar
14. Motzer RJ, Nosov D, Eisen T et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a Phase III trial. J. Clin. Oncol. 31(30), 3791–3799 (2013).
Medline CASGoogle Scholar
15. Choueiri TK, Hessel C, Halabi S et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur. J. Cancer 94, 115–125 (2018).
Medline CASGoogle Scholar
16. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III Trial. J. Clin. Oncol. 28(6), 1061–1068 (2010).
Medline CASGoogle Scholar
17. Amin A, Hammers H. The evolving landscape of immunotherapy-based combinations for frontline treatment of advanced renal cell carcinoma. Front. Immunol. 9, 3120 (2019).
MedlineGoogle Scholar
18. Motzer RJ, Rini BI, McDermott DF et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, Phase III trial. Lancet Oncol. 20(10), 1370–1385 (2019).
Medline CASGoogle Scholar
19. Messerschmidt JL, Prendergast GC, Messerschmidt GL. How cancers escape immune destruction and mechanisms of action for the new significantly active immune therapies: helping nonimmunologists decipher recent advances. Oncologist 21(2), 233–243 (2016).
Medline CASGoogle Scholar
20. Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat. Rev. Cancer 18(3), 139–147 (2018).
Medline CASGoogle Scholar
21. Basic principles of tumor immunology. In: Cancer Immunotherapy Principles and Practice. Butterfield LKaufman HMarincola F (Eds). Demos Medical Publishing, NY, USA, 21–228 (2017).
Google Scholar
22. Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion. Front. Oncol. 8, 386 (2018).
MedlineGoogle Scholar
23. Kawakami Y, Ohta S, Sayem MA, Tsukamoto N, Yaguchi T. Immune-resistant mechanisms in cancer immunotherapy. Int. J. Clin. Oncol. 25(5), 810–817 (2020).
Medline CASGoogle Scholar
24. Fife BT, Pauken KE, Eagar TN et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol. 10(11), 1185–1192 (2009).
Medline CASGoogle Scholar
25. Wu Y, Chen W, Xu ZP, Gu W. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front. Immunol. 10, 2022 (2019).
Medline CASGoogle Scholar
26. Guzik K, Tomala M, Muszak D et al. Development of the inhibitors that target the PD-1/PD-L1 interaction-a brief look at progress on small molecules, peptides and macrocycles. Molecules 24(11), 1–30 (2019).
Google Scholar
27. Rini BI, Plimack ER, Stus V et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380(12), 1116–1127 (2019). •• Landmark study of the combination of pembrolizumab plus axitinib for the first-line management of metastatic renal-cell carcinoma (RCC).
Medline CASGoogle Scholar
28. Motzer RJ, Penkov K, Haanen J et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380(12), 1103–1115 (2019). •• This is the JAVELIN Renal 101 study evaluating the combination of avelumab plus axitinib for treatment of metastatic RCC.
Medline CASGoogle Scholar
29. Wang M, Zhao J, Zhang L et al. Role of tumor microenvironment in tumorigenesis. J. Cancer 8(5), 761–773 (2017).
Medline CASGoogle Scholar
30. Chevrier S, Levine JH, Zanotelli VRT et al. An immune atlas of clear cell renal cell carcinoma. Cell 169(4), 736–749.e18 (2017).
Medline CASGoogle Scholar
31. Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity. Front. Immunol. 9, 978 (2018).
MedlineGoogle Scholar
32. Yasuda S, Sho M, Yamato I et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin. Exp. Immunol. 172(3), 500–506 (2013).
Medline CASGoogle Scholar
33. Hutson TE, Thoreson GR, Figlin RA, Rini BI. The evolution of systemic therapy in metastatic renal cell carcinoma. Am. Soc. Clin. Oncol. Educ. Book 35(36), 113–117 (2016).
MedlineGoogle Scholar
34. Amin A, Plimack ER, Ernstoff MS et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J. Immunother. Cancer 6(1), 109 (2018).
MedlineGoogle Scholar
35. Motzer RJ, Tannir NM, McDermott DF et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378(14), 1277–1290 (2018). •• Landmark Checkmate 214 study of the combination of ipilimumab and nivolumab for first-line treatment of RCC.
Medline CASGoogle Scholar
36. Choueiri TK, Motzer RJ, Rini BI et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann. Oncol. 31(8), 1030–1039 (2020).
Medline CASGoogle Scholar
37. McDermott DF, Huseni MA, Atkins MB et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24(6), 749–757 (2018).
Medline CASGoogle Scholar
38. Motzer RJ, Grünwald V, Hutson TE et al. A Phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma. J. Clin. Oncol. 36(Suppl. 6), TPS706–TPS706 (2018).
Google Scholar
39. Bristol Myers Squibb and Exelixis announce positive topline results from pivotal Phase 3 CheckMate-9ER Trial evaluating opdivo (nivolumab) in combination with cabometyx (cabozantinib) in previously untreated advanced renal cell carcinoma Bristol Myers Squibb. (2020). news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-and-exelixis-announce-positive-topline-re
Google Scholar
40. Bavencio (avelumab) package insert. Merck KGaA, Darmstadt, Germany (2017).
Google Scholar
41. Centanni M, Moes DJAR, Trocóniz I, Ciccolini J, van Hasselt J, Moes DJAR. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin. Pharmacokinet. 58(7), 835–857 (2019).
MedlineGoogle Scholar
42. Boyerinas B, Jochems C, Fantini M et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol. Res. 3(10), 1148–1157 (2015).
Medline CASGoogle Scholar
43. Martins F, Sofiya L, Sykiotis GP et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16(9), 563–580 (2019).
Medline CASGoogle Scholar
44. Heery CR, O'Sullivan-Coyne G, Madan RA et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN solid tumor): a Phase Ia, multicohort, dose-escalation trial. Lancet Oncol. 18(5), 587–598 (2017).
Medline CASGoogle Scholar
45. Arbour KC, Mezquita L, Long N et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J. Clin. Oncol. 36(28), 2872–2878 (2018).
Medline CASGoogle Scholar
46. Scott SC, Pennell NA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J. Thorac. Oncol. 13(11), 1771–1775 (2018).
MedlineGoogle Scholar
47. Horvat TZ, Adel NG, Dang T-O et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J. Clin. Oncol. 33(28), 3193–3198 (2015).
Medline CASGoogle Scholar
48. Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM. Predictors of immunotherapy-induced immune-related adverse events. Curr. Oncol. 25(5), e403–410 (2018).
Medline CASGoogle Scholar
49. Brahmer JR, Lacchetti C, Schneider BJ et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice guideline. J. Clin. Oncol. 36(17), 1714–1768 (2018). •• American Society of Clinical Oncology (ASCO) guidelines for the management of immune-related adverse events.
Medline CASGoogle Scholar
50. Kelly K, Patel MR, Infante JR et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a Phase I, open-label expansion study. J. Clin. Oncol. 33(15), 3044 (2015).
Google Scholar
51. Vaishampayan U, Schöffski P, Ravaud A et al. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: Phase Ib results from the JAVELIN Solid Tumor trial. J. Immunother. Cancer 7(1), 275 (2019).
MedlineGoogle Scholar
52. Kaufman HL, Russell J, Hamid O et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, Phase II trial. Lancet Oncol. 17(10), 1374–1385 (2016).
Medline CASGoogle Scholar
53. Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs RD 11(2), 113–126 (2011).
MedlineGoogle Scholar
54. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011–1027 (2005).
Medline CASGoogle Scholar
55. Hu-Lowe DD, Zou HY, Grazzini ML et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res. 14(22), 7272–7283 (2008).
Medline CASGoogle Scholar
56. Pfizer. Inlyta (axitinib). (2020). https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf
Google Scholar
57. Schmidinger M, Danesi R, Jones R et al. Individualized dosing with axitinib: rationale and practical guidance. Future Oncol. 14(9), 861–875 (2018).
CASGoogle Scholar
58. Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised Phase III trial. Lancet Oncol. 14(6), 552–562 (2013).
Medline CASGoogle Scholar
59. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst. 103(9), 763–773 (2011).
Medline CASGoogle Scholar
60. Hutson TE, Lesovo V, Al-Shukri S et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label Phase III trial. Lancet Oncol. 14(13), 1287–1294 (2013).
Medline CASGoogle Scholar
61. Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol. Cancer 18(1), 60 (2019). • Outlines the important synergistic effect of combining immunotherapy with anti-angiogenic agents.
MedlineGoogle Scholar
62. Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression. Clin. Cancer Res. Clincanres 25(18), 5449–5457 (2019).
Medline CASGoogle Scholar
63. Choueiri TK, Larkin J, Oya M et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, Phase Ib trial. Lancet Oncol. 19(4), 451–460 (2018).
Medline CASGoogle Scholar
64. Voss MH, Motzer RJ, Albiges L et al. Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101. J. Clin. Oncol. 38(6), 690 (2020).
Google Scholar
65. Lampson LA. Editorial: immunotherapy for tumor in the brain: insights from-and for-other tumor sites. Front. Oncol. 8, 128 (2018).
MedlineGoogle Scholar
66. Jonasch E, Hasanov E, Motzer RJ et al. Evaluation of brain metastasis in JAVELIN Renal 101: efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S). J. Clin. Oncol. 38(6), 687 (2020).
Google Scholar
67. Cella D, Grünwald V, Escudier B et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, Phase III trial. Lancet Oncol. 20(2), 297–310 (2019).
Medline CASGoogle Scholar
68. Zhu J, Armstrong AJ, Friedlander TW et al. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J. Immunother. Cancer 6(1), 4 (2019). • Review of the current status of biomarkers in RCC, the area of greatest unmet need in management of this malignancy.
Google Scholar
69. Zhang X, Yin X, Zhang H et al. Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. BMC Cancer 19(1), 360 (2019).
MedlineGoogle Scholar
70. Choueiri TK, Motzer RJ, Campbell MT et al. Subgroup analysis from JAVELIN Renal 101: outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). J. Clin. Oncol. 37(7), 544 (2019).
Google Scholar
71. Plimack ER, Rini BI, Stus V et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. J. Clin. Oncol. 38(Suppl. 15), 5001 (2020).
Google Scholar
72. Choueiri TK, Albiges L, Haanen JBAG et al. Biomarker analyses from JAVELIN Renal 101: avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). J. Clin. Oncol. 37(15), 101 (2019).
Google Scholar
73. Choueiri TK, Haanen JBAG, Larkin JMG et al. Molecular characteristics of renal cell carcinoma (RCC) risk groups from JAVELIN Renal 101. J. Clin. Oncol. 38(6), 744 (2020).
MedlineGoogle Scholar
74. Bacon JVW, Annala M, Soleimani M et al. Plasma circulating tumor DNA and clonal hematopoiesis in metastatic renal cell carcinoma. Clin. Genitourin. Cancer 18(4), 322–331.e2 (2020).
MedlineGoogle Scholar
75. Nappi L, Bacon J, Annala M et al. Detection of circulating tumor DNA in patients with metastatic clear cell renal cell carcinoma. J. Clin. Oncol. 37(15), e16105 (2019).
Google Scholar
76. Farber NJ, Kim CJ, Modi PK, Hon JD, Sadimin ET, Singer EA. Renal cell carcinoma: the search for a reliable biomarker. Transl. Cancer Res. 6(3), 620–632 (2017).
Medline CASGoogle Scholar
77. Labriola M, Zhu J, Gupta R et al. Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 37(7), 589 (2019).
MedlineGoogle Scholar
78. Lee C-H, DiNatale RG, Chowell D et al. Genomic biomarkers of response to lenvatinib/pembrolizumab (len/pembro) in patients with advanced renal cell carcinoma. J. Clin. Oncol. 38(6), 733 (2020).
Google Scholar
79. Derosa L, Iebba V, Albiges L et al. Gut microbiome composition to predict resistance in renal cell carcinoma (RCC) patients on nivolumab. J. Clin. Oncol. 36(15), 4519 (2018).
Google Scholar
80. Agarwal A, Modliszewski J, Davey L et al. Investigating the role of the gastrointestinal microbiome in response to immune checkpoint inhibitors (ICIs) among patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 38(6), 730 (2020).
Google Scholar
81. Bergerot PG, Dizman N, Ruel N, Frankel PH, Hsu J, Pal SK. A Phase I trial to assess the biologic effect of CBM588 (Clostridium butyricum) in combination with nivolumab plus ipilimumab (nivo/ipi) in patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 38(6), TPS764 (2020).
Google Scholar
82. De Mello RA, Ayoub E, Castelo-Branco P et al. Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the U.K. perspective. J. Clin. Oncol. 38(6), 689 (2020).
Google Scholar
83. Long GV, Tykodi SS, Schneider JG et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann. Oncol. 29(11), 2208–2213 (2018).
Medline CASGoogle Scholar
84. US FDA. FDA approves new dosing regimen for pembrolizumab. (2020). https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-new-dosing-regimen-pembrolizumab
Google Scholar
85. Escudier B, Porta C, Schmidinger M et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30(5), 706–720 (2019).
Medline CASGoogle Scholar
86. Motzer RJ, Jonasch E, Michaelson MD et al. NCCN Guidelines insights: kidney cancer, version 2.2020. J. Natl Compr. Cancer Netw. J. Natl Compr. Canc. Netw. 17(11), 1278–1285 (2019).
Medline CASGoogle Scholar
87. Hotte SJ, Kapoor A, Basappa NS et al. Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Can. Urol. Assoc. J. 13(10), 343–354 (2019).
MedlineGoogle Scholar
88. Tannir NM, McDermott DF, Escudier B et al. Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: first-line nivolumab + ipilimumab (N + I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J. Clin. Oncol. 38(6), 609 (2020).
Google Scholar
89. Duan J, Cui L, Zhao X et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol. 6(3), 375–384 (2020).
MedlineGoogle Scholar

Vol. 16, No. 36

Metrics

Downloaded 287 times

History

Received 7 June 2020

Accepted 11 August 2020

Published online 28 August 2020

Published in print December 2020

Information

Keywords

Financial & competing interests disclosure

M Soleimani received funding from Pfizer. C Kollmannsberger received funding from Pfizer, Novartis and Bristol-Myers Squibb; C Kollmannsberger has also held consulting/advisory roles for Pfizer, Novartis, Bristol-Myers Squibb, Pharma, Ipsen, Eisai and Janssen; C Kollmannsberger's travel, accomodations and expenses have been paid for by Pfizer, Novartis and Eisai. L Nappi received funding from Astellas Pharma and Pfizer; L Nappi also has patents, royalties, other intellectual property: ivermectin analogue compound therapeutics for heat shock protein-27 (HSP27) inhibition, methods and uses associated there with provisional no. 62/756,707. L Nappi's travel, accomodations and expenses have been paid for by Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Company review disclosure

In addition to the peer-review process, with the author's consent, the manufacturer of the product discussed in this article was given the opportunity to review the manuscript for factual accuracy. Changes were made by the author at their discretion and based on scientific or editorial merit only. The author maintained full control over the manuscript, including content, wording and conclusions.

PDF download

Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma

Abstract

References